Open AccessManagement of Moderate and Severe Forms of Psoriasis in Children: New Opportunities of Genetically Engineered Biologic Drugs
Author(s) -
Leyla Namazova-Baranova,
А. Л. Бакулев,
Nikolay N. Murachkin,
Lyudmila N. Nam,
Р. А. Иванов
Publication year - 2021
Publication title -
voprosy sovremennoj pediatrii
Language(s) - English
Resource type - Journals
eISSN - 1682-5535
pISSN - 1682-5527
DOI - 10.15690/vsp.v20i5.2322
Subject(s) - secukinumab , psoriasis , medicine , dermatology , ixekizumab , plaque psoriasis , clinical trial , safety profile , drug , lesion , immunology , pharmacology , surgery , adverse effect , psoriatic arthritis
The article shows the key role of IL-17 in the psoriasis pathogenesis and the opportunities of its management via monoclonal antibodies product secukinumab. The review of international randomized trials on clinical efficacy and safety of genetically engineered biologic drug secukinumab in children and adolescents with psoriasis is presented. During treatment periods of 12 to 52 weeks, secukinumab has shown high therapeutic efficacy for psoriasis severity and skin lesion areas and has improved quality of life of children and adolescents according to dynamic assessments of PASI, IGA 0/1 mod 2011 indices, CDLQI questionnaire. The safety profile of secukinumab in children is estimated as favorable and comparable to using it in adults.